Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 1
2001 1
2002 1
2003 2
2004 2
2005 1
2006 3
2007 1
2008 4
2009 6
2010 3
2011 5
2012 9
2013 6
2014 4
2015 9
2016 3
2017 2
2019 2
2022 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: hoeflich kp. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
p21-activated kinase inhibitors.
Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J. Rudolph J, et al. Among authors: hoeflich kp. Enzymes. 2013;34 Pt. B:157-80. doi: 10.1016/B978-0-12-420146-0.00007-X. Epub 2013 Nov 7. Enzymes. 2013. PMID: 25034104 Review.
Targeting cancer with kinase inhibitors.
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Gross S, et al. Among authors: hoeflich kp. J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1. J Clin Invest. 2015. PMID: 25932675 Free PMC article. Review.
p21-activated kinase 1: PAK'ed with potential.
Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Ong CC, et al. Among authors: hoeflich kp. Oncotarget. 2011 Jun;2(6):491-6. doi: 10.18632/oncotarget.271. Oncotarget. 2011. PMID: 21653999 Free PMC article. Review.
p21-Activated kinase inhibitors: a patent review.
Crawford JJ, Hoeflich KP, Rudolph J. Crawford JJ, et al. Among authors: hoeflich kp. Expert Opin Ther Pat. 2012 Mar;22(3):293-310. doi: 10.1517/13543776.2012.668758. Epub 2012 Mar 11. Expert Opin Ther Pat. 2012. PMID: 22404134 Review.
Radixin: cytoskeletal adopter and signaling protein.
Hoeflich KP, Ikura M. Hoeflich KP, et al. Int J Biochem Cell Biol. 2004 Nov;36(11):2131-6. doi: 10.1016/j.biocel.2003.11.018. Int J Biochem Cell Biol. 2004. PMID: 15313460 Review.
Inhibitors of p21-activated kinases (PAKs).
Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Rudolph J, et al. Among authors: hoeflich kp. J Med Chem. 2015 Jan 8;58(1):111-29. doi: 10.1021/jm501613q. Epub 2014 Dec 3. J Med Chem. 2015. PMID: 25415869
Midpoint Reflections on USAID HIV Local Partner Transition Efforts.
Kaliel D, Knight C, Avery L, White LA, Bonanno L, Porter J, Hoeflich K, Irwin C, Nikola C, Paul A, Hijazi M, Cavanaugh C, Raulfs-Wang EC. Kaliel D, et al. Among authors: hoeflich k. Glob Health Sci Pract. 2023 Jun 21;11(3):e2200338. doi: 10.9745/GHSP-D-22-00338. Print 2023 Jun 21. Glob Health Sci Pract. 2023. PMID: 37348951 Free PMC article.
66 results